System identification of photosensitiser uptake kinetics in photodynamic therapy
Thierry Bastogne, Loraine Tirand, Muriel Barberi-Heyob, Alain Richard

To cite this version:
SYSTEM IDENTIFICATION OF PHOTOSENSITISER UPTAKE KINETICS IN PHOTODYNAMIC THERAPY

T. Bastogne * L. Tirand ** M. Barberi-Heyob ** A. Richard *

Abstract: This study presents the contributions of system identification techniques to the experimental modelling of photosensitiser uptake kinetics in photodynamic therapy. The experimental framework is limited to one cancer cell line (HT29-A4), one photosensitiser (Chlorin e6), one photosensitiser dose ($5\mu g \cdot ml^{-1}$), four albumin rates in a monolayer culture and eight measurements between 1h and 24h. Issues associated with this experimental modelling study are the deficiency of measurement points, low signal-to-noise ratios and 'poor' excitation signals (step signals). This paper deals with model structure selection, parameter estimation and parameter uncertainty description by probabilistic confidence regions. Moreover, an explicit relationship between the static gain of the estimated model and the albumin rate of the culture medium has been established *.

* Université Henri Poincaré, Nancy 1, Centre de Recherche en Automatique de Nancy (CRAN), CNRS-INPL-UHP UMR 7039, BP 239, F-54506 Vandœuvre-lès-Nancy Cedex, France
** Centre Alexis Vautrin, Centre de Lutte contre le Cancer Brabois, Av. de Bourgogne, 54511 Vandœuvre-lès-Nancy Cedex

Keywords: system identification, pharmacokinetics, drug delivery, photodynamic therapy

1. INTRODUCTION

Photodynamic therapy (PDT) (Moser, 1998) is an emerging therapy for displastic tissues such as cancers. This therapy involves selective uptake and retention of a photosensitive drug (photosensitiser, PS) in a tumour, followed by irradiation with light at an appropriate wavelength. The activated photosensitiser is thought to produce singlet oxygen at high doses and thereby to initiate apoptotic and necrotic death of tumour. In current clinical practice, photodynamic therapy is carried out with prescribed drug doses and light doses as well as fixed drug-light intervals and illumination fluence rates. These doses are determined from a physical model, see e.g. (Patterson et al., 1990; Hetzel et al., 2005), defined in equation (1).

$$[R] = k_s \cdot b \cdot \epsilon \cdot I_{\lambda} \cdot T \cdot [1\ P] \cdot \Phi \cdot f$$

where: $[R]$ is a threshold concentration of oxidising events radicals that needs to occur in a sensitive location within a cancer cell to elicit the cascade toward cell death, $I_{\lambda}$ is the irradiance on the tissue surface, $T$ is the exposure time of treatment light and $[1\ P]$ is the concentration of intracellular photosensitive drug (photosensitiser P). $k_s$ is the backscatter factor due to reflected light from underlying tissue, $b$ is a conversion factor, $\epsilon$ is the extinction coefficient of photosensitive drug, $\Phi$ is the quantum yield for conversion of activated drug to oxidising radicals, which usually depends on the oxygen concentration dissolved in the cells and $f$ is the fraction of generated oxidising radicals, which attack sensitive cellular sites, while the fraction $(1-f)$ of the radicals attack lesser
sites and have minor effect. Despite its current use in clinical applications, several polemical points can be addressed against this model:

- Equation (1) shows a simple reciprocity of photosensitiser concentration and light. Nevertheless, several experiments have shown contradictory results (Moesta et al., 1995; Yuan et al., 1997). Moreover Potter et al. have shown that a reduction in photosensitiser concentration during treatment, e.g. PS photodegradation, is an important consideration (Potter, 1986).
- The term (Φ) is function of oxygenation but is usually a unknown factor during PDT (Tromberg et al., 1990; Nichols and Foster, 1994; Hetzel et al., 2005; Dysart et al., 2005).
- Sites of photodamage mainly depend on the location of the PS in the cell. Sites of action for singlet oxygen in PDT include mitochondria, endoplasmic reticulum, Golgi apparatus, lysosomes, DNA and lipid membranes (Henderson and Dougherty, 1992; Epe et al., 1993). Some of them are critical sites. Unfortunately, equation (1) does not take into account the intracellular location of PS.
- In fact, all quantities are generally time dependent, i.e. their concentrations (or in the case of light, its fluence rate) can change during irradiation. In other words, PDT is a dynamic process but equation (1) is just a static model (Georgakoudi et al., 1997; Georgakoudi and Foster, 1998; Dysart et al., 2005).

This previous list is not exhaustive but presents some of the main modelling requirements and challenges for increasing scientific knowledge of PDT. System identification (Ljung, 1987; Söderström and Stoica, 1989; Walter and Pronzato, 1997) is the field of mathematical modelling of dynamic systems from experimental data. No identification study has ever been applied to the PDT problem. It is therefore interesting to assess the contributions of system identification to the experimental modelling of PDT.

The problem addressed in this paper deals with system identification of in vitro photosensitiser uptake kinetics, i.e. the first phase of PDT. Problems encountered are generic problems in biology, i.e. few measurement points (n<sub>e</sub>·n<sub>t</sub> < 20), low signal-to-noise ratios due to a great measurement variability and ‘poor’ stimulus signals (step signals in general). In this experimental framework, objectives are: (1) selecting a model structure (M(x)), (2) estimating its parameters (p), (3) determining the parameter uncertainties and if necessary explaining how the serum concentration in the culture medium ([S<sub>e</sub>]) can influence model parameters, i.e. determining the relationship f(·) such that <math>\hat{p} = f([S_e])</math>.

This paper is organised as follows. A macroscopic model of PDT is firstly presented in section 2 to introduce the system identification problem of PS uptake kinetics under a restricting experimental framework. The remaining sections are put into a chronological order of system identification steps. Section 3 deals with model structure selection, section 4 presents the estimation step, section 5 describes the parameter uncertainty, section 6 concerns the validation of the noise hypothesis and section 7 discusses on the explicit influence of the serum concentration.

### 2. MATHEMATICAL MODEL OF PDT

#### 2.1 Macroscopic model

<table>
<thead>
<tr>
<th>Table 1. Main notations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symb.</td>
</tr>
<tr>
<td>[x]</td>
</tr>
<tr>
<td>Q&lt;sub&gt;x&lt;/sub&gt;</td>
</tr>
<tr>
<td>D&lt;sub&gt;x&lt;/sub&gt;</td>
</tr>
<tr>
<td>t</td>
</tr>
<tr>
<td>P</td>
</tr>
<tr>
<td>P&lt;sub&gt;n&lt;/sub&gt;</td>
</tr>
<tr>
<td>P&lt;sub&gt;i&lt;/sub&gt;</td>
</tr>
<tr>
<td>P&lt;sub&gt;e&lt;/sub&gt;</td>
</tr>
<tr>
<td>P&lt;sub&gt;PR&lt;/sub&gt;</td>
</tr>
<tr>
<td>z&lt;sub&gt;p&lt;/sub&gt;</td>
</tr>
<tr>
<td>M</td>
</tr>
<tr>
<td>S&lt;sub&gt;e&lt;/sub&gt;</td>
</tr>
<tr>
<td>CCL</td>
</tr>
<tr>
<td>A&lt;sub&gt;th&lt;/sub&gt;</td>
</tr>
<tr>
<td>L</td>
</tr>
<tr>
<td>I&lt;sub&gt;s&lt;/sub&gt;</td>
</tr>
<tr>
<td>S</td>
</tr>
<tr>
<td>P</td>
</tr>
<tr>
<td>M(·)</td>
</tr>
<tr>
<td>s</td>
</tr>
<tr>
<td>n&lt;sub&gt;e&lt;/sub&gt;</td>
</tr>
<tr>
<td>n&lt;sub&gt;t&lt;/sub&gt;</td>
</tr>
<tr>
<td>SNR</td>
</tr>
</tbody>
</table>

A macroscopic model of PDT is described by a block diagram in figure 1. Main variables, except the standard notations of chemical elements, are given in table 1. This macroscopic model is composed of three macro-blocks associated with the three main phases of PDT, i.e. the PS uptake, the irradiation and the cytotoxicity phases. The photosensitiser, light generator, cell culture medium and cancer cell line are described by signal generators (grey blocks). The main input variables, I<sub>s</sub>, Q<sub>Pn</sub> and [O<sub>2</sub>] are represented by bold arrows. [S<sub>e</sub>] and CCL are usually supposed to be constant during the therapy. λ is regarded as a parameter of the light source. The PS uptake and cytotoxicity phases are described by black-box models since their dynamic behaviour is not well understood currently. e<sub>P</sub>, e<sub>[O2]</sub>, e<sub>S</sub> are error variables describing the combined effects of modelling errors, measurement noises and disturbances.

#### 2.2 PS uptake kinetics

A sketch of the PS uptake phenomenon under in vitro condition is shown in figure 2. During this phase, a mass balance equation applied to the PS molecules is:
The uptake kinetics between the input variable $Q_{Pa}$ (step magnitude $\epsilon$) and the output variable $Q_{P1}(t)$ is described as follows:

$$Q_{P1}(t) = M(t, p, Q_{Pa}) + e(t)$$

(3)

where the model structure $M(\cdot)$ and its parameters $p$ are unknown. $e(t)$ corresponds to the output error, i.e. the error between the measured output $(Q_{P1}(t))$ and the model output $(\hat{Q}_{P1}(t) = M(t, p, Q_{Pa}))$. $e(t)$ is assumed to be a random variable with a normal distribution defined by $\pi(e(t)) \propto \mathcal{N}(0, \sigma^2)$. The sequence $e = \{e(t_1) \cdots e(t_n)\}$ is supposed to be independent and identically distributed.

### 3. Selection of a Kinetic Model Structure

The first question deals with the determination of a parsimonious model structure ($\langle M(p) \rangle$) among a set $\mathcal{M}$ of candidate model structures. Three a priori distinguishable model structures (Walter and Pronzato, 1997) are examined, $\mathcal{M} = \{M_1, M_2, M_3\}$ with:

$M_1$: $(1 + T_1 \cdot s)Q_{P1}(t) = k_1 \cdot Q_{Pa}(t);$

$M_2$: $Q_{P1}(t) = k_1 \cdot Q_{Pa}(t);$

$M_3$: $Q_{P1}(t) = k_1 \cdot Q_{Pa}(t) + k_2 \cdot e(t).$
The parameter estimation relies on the output error method for a parallel model as shown in figure 5 in which the optimisation step is based on a Levenberg Marquardt algorithm. Estimates of $p_i = (k_1, T_1)$ are given in table 2. Figure 7 compares the measured (mean values) and simulated step responses of $Q_{P_i}$ for the four different albumin rates.

### Table 2. Estimation results

<table>
<thead>
<tr>
<th>$[Se]$ (%)</th>
<th>0%</th>
<th>2%</th>
<th>5%</th>
<th>9%</th>
</tr>
</thead>
<tbody>
<tr>
<td>$k_1$</td>
<td>501</td>
<td>257</td>
<td>117</td>
<td>81</td>
</tr>
<tr>
<td>$T_1$ (h)</td>
<td>3.19</td>
<td>2.93</td>
<td>2.02</td>
<td>2.03</td>
</tr>
</tbody>
</table>

### 5. Parameter uncertainty

Determining the optimal value of the parameters with respect to a chosen criterion is not enough. It is also important to evaluate the uncertainty associated with those estimates. Herein, parameters uncertainty is described by confidence regions, noted $R^\alpha$, defined in (Hamilton et al., 1982; Walter and Pronzato, 1997) as follows:

$$R^\alpha = \left\{ p \in \mathbb{R}^{n_p} \mid \frac{e^T(p)\Pi(p)e(p)}{n_p\sigma^2} \leq F_\alpha(n_p, n_e - 1) \right\}$$

$R^\alpha$ defines a $100(1 - \alpha)$% confidence region for the parameters. $F_\alpha(n_1, n_2)$ denotes a Fisher-Snedecor distribution with $n_1$ and $n_2$ degrees of freedom. $e(p) = Q_{P_i} - Q_{\hat{P}_i}$ is the output error vector in $\mathbb{R}^{n_e}$. The orthogonal projection matrix $\Pi(p)$ is given by:

$$\Pi(p) = S_{Q_{P_i}}^{-1}S_{Q_{\hat{P}_i}}^{-1}S_{Q_{P_i}}^T,$$

where $S_{Q_{\hat{P}_i}} = \partial Q_{\hat{P}_i}/\partial p^T$ is the sensitivity function (gradient) of the output model in respect with the parameter vector. The estimated noise variance is given by:
\[
\hat{\sigma}^2 = \frac{1}{n_c n_t} - 1 \sum_{i=1}^{n_t} \sum_{k=1}^{n_c} (Q_{P_i}(t_{i,k}) - \hat{Q}_{P_i,i})^2
\]
\[
\hat{Q}_{P_i,i} = \frac{1}{n_c} \sum_{k=1}^{n_c} Q_{P_i}(t_{i,k}).
\]

\(n_c\) refers to the number of repeated experiments. Figure 8 shows the four 95\% confidence regions associated with the four values of the albumin rate. This result reveals a large uncertainty about the estimates, mainly for \(T_1\). The number of time instants cannot be significantly increased in practice. Nevertheless, adapting materials and measurement systems in order to increase the number of samples at each time instant is possible. This solution could significantly reduce the area of confidence regions.

\[\text{Figure 8. 95\% confidence regions for } \hat{k}_1 \text{ and } \hat{T}_1\]

6. NOISE HYPOTHESIS VALIDATION

The determination of the confidence regions relies on the assumption that \(\{e(t_i, p)\}\) is a sequence of normal random variables, independent and identically distributed, i.e. \(e(t_i, p) \sim \mathcal{N}(0, \sigma_e^2)\). Histograms of output residuals are depicted in figure 9. Their empirical distribution is clearly dependent on the serum rates (\([Se]\)). Unfortunately, the number of realisations is too small (\(\leq 20\)) to accurately check the Gaussian distribution of the residuals. However, the assumption about the nullity of the mean is perceptibly valid. Moreover, almost all histograms are symmetric. There is thereby no convincing reason to reject the initial hypothesis. In other terms, no conclusion can be drawn about the validity of the noise assumption. In fact, in this experimental setup, the gaussian and i.i.d. assumption, usual stochastic paradigm in system identification, is not suited to the description of the parameter uncertainty. In perspective, it would be interesting to assess recent alternative approaches like the interval analysis (Jaulin et al., 2001) or the Leave-out Sign-dominant Correlation Regions proposed by Campi and Weyer in (Campi and Weyer, 2006).

\[\text{Figure 9. Histograms of output residuals for } M_1\]

7. ANALYSIS OF THE SERUM DEPENDANCE

Figure 10(a) shows that \(\hat{k}_1\) is a decreasing function of \([Se]\). The dotted graph refers to the four estimates of \(k_1\) and the continuous curve is a regression model, defined in equation (9).

\[
\hat{k}_1 \approx \frac{922}{[Se] + 1.83}.
\]

This model expresses an inversely proportional relationship between the static gain \(\hat{k}_1\) and the serum rate \([Se]\). A new \textit{in vitro} model (monolayer culture) of the PS uptake kinetic, defined in equation 10, can thereby be put forward.

\[
T_1 \hat{Q}_{P_i}(t) + \hat{Q}_{P_i}(t) = \frac{\alpha}{[Se] + \beta} \cdot Q_{P_i}(t) + e(t),
\]

where the parameters \(T_1, \alpha\) and \(\beta\) are functions of the cancer cell line. The output error \(e(t)\) is supposed to be an independent stochastic process normally distributed \(\mathcal{N}(0, \sigma^2)\). No significant relationship has been pointed out between \(T_1\) and \([Se]\).

\[\text{Figure 10. Relationship between } \hat{k}_1 \text{ and } [Se] \text{ for two different CCL}\]
8. MODEL VALIDATION

The previous model has not been cross validated yet but a similar model, i.e. a first-order model, has been identified for another cancer cell line (HT29, BLK). Figure 10(b) corroborate the inversely proportional relationship between \( k_1 \) and \([S]\) for the HT29, BLK line.

9. CONCLUSION

Contributions of system identification to the in vitro modelling of photosensitiser uptake kinetics in photodynamic therapy are examined in this study. Difficulties of such an application are triple: (i) lack of measurement, (ii) low signal-to-noise ratio and (iii) ‘poor’ stimulus signals. The identification procedure deals with model structure selection, parameter estimation, uncertainty description and model validation. The resulting behavioural model relies on a first-order differential equation taking into account the effects of the protein factor. This result has confirmed the applicability of system identification algorithms in such an experimental setup. However, estimates are characterized by large confidence regions. The number of time instants cannot be significantly increased in practice. Nevertheless, adapting materials and measurement systems in order to increase the number of samples at each time instant is possible. Future experiments will be carried out to check the validity of the proposed behavioural model for other photosensitisers and cancer cell lines.

REFERENCES


